Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Cell populations which co-express CD49c and CD90

a technology of cd49c and cd90, which is applied in the field of cell populations which co-express cd49c and cd90, can solve the problems of cord) and peripheral nervous system adversely affecting humans, and achieve the effects of reducing or repairing loss, improving quality of life and life expectancy, and facilitating repair

Inactive Publication Date: 2007-10-04
GARNET BIOTHERAPEUTICS
View PDF51 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0028] The invention described herein provides a substantially homogenous population of cells for treating a condition or disease in a human. Advantages of the cell based therapies of the claimed invention include, for example, incorporation of the cells into the tissue (e.g., central nervous system tissue, peripheral nervous system tissue, cardiac tissue); the incorporated cells have the potential to differentiate or develop into neuronal, glial or other cells (e.g., cardiac muscle) to replace or facilitate repair of the damaged, traumatized or degenerating tissue thereby resulting in a more permanent treatment of the degenerative, acute injury, traumatized, neurological or cardiac condition; and the ability to employ characterized reproducible populations of cells in treatment regimens. The cells of the invention have the potential to secret beneficial cytokines and trophic factors (e.g., BDNF, IL-6, NGF and MCP-1).
[0029] Thus, treatment of humans with populations of cells which co-express CD49c and CD90 can potentially reverse, diminish or repair the loss due to a degenerative, acute injury, neurological or cardiac condition in a human, thereby increasing the quality of life and life expectancy for the human.

Problems solved by technology

A number of conditions and diseases of the central (brain and spinal cord) and peripheral nervous system adversely affect humans.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cell populations which co-express CD49c and CD90
  • Cell populations which co-express CD49c and CD90
  • Cell populations which co-express CD49c and CD90

Examples

Experimental program
Comparison scheme
Effect test

example 1

Isolation of a Adherent as Colony Forming Units of Cells or “CFUs” From Bone Marrow Aspirates Following Red Blood Cell Lysis

[0116] Bone marrow cells were aspirated from the iliac crest of healthy adult human volunteers. The red blood cell component of the aspirate was lysed by mixing the aspirate with an ammonium chloride buffer consisting of 155 mM ammonium chloride, 10 mM potassium bicarbonate and 0.1 mM EDTA (ethylenediaminetetraacetic acid), pH 7.2, at a 1:20 ratio of marrow aspirate to buffer. The resulting cell suspension was vortexed for 2 seconds, incubated for 2 minutes at ambient temperature and then centrifuged (10 minute at 500×g). The resulting mononuclear cell pellet was resuspended in complete medium and centrifuged (10 minutes at 500×g). Complete media is Minimal Essential Medium-alpha (Gibco BRL, Rockville, Md.) supplemented with 4 mM glutamine and 10% sera-lot selected fetal bovine serum (FBS, Gibco BRL, Rockville, Md.). The cell pellet was then re-suspended in th...

example 2

Isolation of a Adherent CFUs From Bone Marrow Aspirates Following Density Separation

[0121] Bone marrow cells were aspirated from the iliac crest of healthy adult human volunteers. The bone marrow aspirate was diluted with calcium and magnesium free phosphate buffered saline (PBS) to achieve a mononuclear cell concentration of 7×106 cells / mL and overlaid onto an equal volume of Histopaque® 1.119 (Sigma, St. Louis, Mo.) and centrifuged (30 min at 700×g). The resulting mononuclear cell fraction was transferred to a clean centrifuge tube containing PBS and centrifuged (10 minutes at 500×g). The cell pellet was re-suspended in PBS and centrifuged (10 minutes at 500×g). The supernatant was aspirated from the cell pellet and the cells re-suspended in complete media.

[0122] The number of viable cells in the resulting cell suspension was determined by trypan blue-exclusion. The cell suspension was then seeded in tissue culture-treated T75 flasks at a density of 50,000 cells / cm2 and incubate...

example 3

Production of Primary and Master Cell Banks from CFUs

[0124] After 7-10 days in culture, the CFUs generated using the methods described in Example 1 were removed from the T75 flasks with a 0.25% trypsin / 1 mM EDTA solution (Life Technologies). After 10 minutes at 37° C., the trypsin was inactivated with 10 mL of complete medium. The cells were washed once with HBSS and re-suspended in Glycerol Cell Freezing Medium® (Sigma Chemical Co.). Aliquots (referred to herein as “the Primary Cell Bank”) of the suspension consisting of 4.0×105 cells / vial were cooled with liquid nitrogen vapor at 1° C. / minute using a CryoMed (Forma) controlled rate freezer and the stored in a Cryo Plus liquid nitrogen storage tank (Forma).

[0125] An aliquot of cells was removed from the Primary Cell Bank and cultured at a density of 30 cells / cm2 in 500 cm2 tissue culture-treated plates (Corning) in complete medium and incubated at 37° C. in an atmosphere consisting of 5% carbon dioxide, 5% oxygen, and 90% nitroge...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
doubling timeaaaaaaaaaa
doubling timeaaaaaaaaaa
doubling timeaaaaaaaaaa
Login to View More

Abstract

Substantially homogenous cells populations which co-express CD49c, CD90 and telomerase are made. In one embodiment, humans suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition are treated with the substantially homogenous cells populations which co-express CD49c, CD90 and telomerase. In another embodiment, committed progenitor cells are made are made by selecting from a cultured source of a cell population which co-express CD49c and CD90 and modifying the cell population. The committed progenitor cells can be employed to treat a human suffering from a degenerative, traumatic, acute injury cardiac or neurological condition and formulate pharmaceutical compositions.

Description

RELATED APPLICATION [0001] This application is a divisional of U.S. application Ser. No. 09 / 9,50,244, filed Sep. 21, 2001. The entire teachings of the above application are incorporated herein by reference.BACKGROUND OF THE INVENTION [0002] A number of conditions and diseases of the central (brain and spinal cord) and peripheral nervous system adversely affect humans. These conditions and diseases include, for example, spinal cord injury, amyotrophic lateral sclerosis (ALS), Parkinson's disease, stroke, traumatic brain injury, brain tumors and Fabry Disease. Clinical management strategies frequently focus of the prevention of further neurological damage or injury rather than replacement or repair of the damaged neurological tissue (e.g., neurons, glial cells); include treatment with exogenous steroids and synthetic, non-cellular pharmaceutical drugs; and have varying degrees of success which may depend on the continued administration of the steroid or synthetic drug. [0003] For exam...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K48/00C12N15/09A61K35/12A61K35/28A61K35/34A61K35/36A61K35/44A61K35/50A61P9/04A61P9/10A61P19/08A61P21/04A61P25/00A61P25/16A61P35/00C12N5/0775C12N5/0797
CPCA61K2035/124C12N5/0623C12N2500/02C12N5/0673C12N5/0663C12N2506/1353C12N2500/32C12N5/0669A61P19/08A61P21/00A61P21/04A61P25/00A61P25/02A61P25/16A61P25/28A61P35/00A61P43/00A61P5/00A61P9/00A61P9/04A61P9/10
Inventor HO, TONY W.KOPEN, GENE C.RIGHTER, WILLIAM F.RUTKOWSKI, J. LYNNWAGNER, JOSEPH
Owner GARNET BIOTHERAPEUTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com